Clinical Response to Infliximab after Secondary Failure with Adalimumab or Certolizumab Pegol in Crohn's Disease

被引：0
|
作者：
Trivella, Juan [1 ]
Yarur, Andres [1 ]
Moroney, James [1 ]
Deshpande, Amar [1 ]
Abreu, Maria [1 ]
Sussman, Daniel [1 ]
机构：
[1] Univ Miami, Jackson Mem Hosp, Miami, FL 33136 USA
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2013年 / 108卷
关键词：
D O I：
10.14309/00000434-201310001-01855
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1855
引用
收藏
页码：S560 / S561
页数：2
相关论文
共 50 条
  • [1] CERTOLIZUMAB PEGOL IN CROHN'S DISEASE REFRACTORY TO INFLIXIMAB AND ADALIMUMAB
    Jose, Morales Lara Ma
    Penella Monica, Martinez
    Guzman Diana, Lacruz
    Vidal Vanessa, Jorge
    Maneiro Vicente, Santaclara
    Sanchez Senador, Moran
    del Carmen, Mira Sirvent Ma
    ATENCION FARMACEUTICA, 2009, 11 (03): : 178 - 180
  • [2] Certolizumab Pegol in Patients With Moderate to Severe Crohn's Disease and Secondary Failure to Infliximab
    Sandborn, William J.
    Abreu, Maria T.
    D'Haens, Geert
    Colombel, Jean-Frederic
    Vermeire, Severine
    Mitchev, Krassimir
    Jamoul, Corinne
    Fedorak, Richard N.
    Spehlmann, Martina E.
    Wolf, Douglas C.
    Lee, Scott
    Rutgeerts, Paul
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2010, 8 (08) : 688 - 695
  • [3] Crohn's disease - infliximab, adalimumab and certolizumab-pegol: clinical value of anti-TNF-α treatment
    Schreiber, S.
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2007, 132 (34-35) : 1770 - 1774
  • [4] Efficacy of certolizumab pegol in Crohn's disease patients with secondary failure to infliximab is not affected by concommittant medications
    Sandborn, W.
    Vermerie, S.
    Abreu, M.
    D'Haens, G.
    Colombel, J.
    Mitchev, K.
    Jamoul, C.
    Fedorak, R.
    Spehlmann, M.
    Wolf, D.
    Lee, S.
    Rutgeerts, P.
    INFLAMMATORY BOWEL DISEASES, 2009, 15 (12) : S15 - S16
  • [5] Efficacy of Certolizumab Pegol in Crohn's Disease Patients with Secondary Failure to Infliximab Is Not Affected by Concomitant Medications
    Sandborn, William
    Vermeire, Severine
    Abreu, Maria
    D'Haens, Geert
    Colombel, Jean-Frederick
    Mitchev, Krassimir
    Jamoul, Corinne
    Fedorak, Richard
    Spehlmann, Martina
    Wolf, Douglas
    Lee, Scott
    Rutgeerts, Paul
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2009, 104 : S451 - S452
  • [6] Estimation of induction and maintenance costs of infliximab, adalimumab and certolizumab pegol in managing Crohn's disease
    Feagan, Brian
    Tan, Seng
    Malone, Daniel
    Hinojosa, Joaquin
    Brown, Martin
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2008, 103 : S392 - S392
  • [7] Estimation of induction and maintenance costs of Infliximab, Adalimumab and Certolizumab Pegol in managing Crohn's Disease
    Feagan, B.
    Tan, S.
    Malone, D.
    Hinojosa, J.
    Brown, M.
    INFLAMMATORY BOWEL DISEASES, 2008, 14 (12) : S33 - S33
  • [8] Efficacy of Certolizumab Pegol is Not Affected by Baseline Anti-infliximab Antibody Status in Patients with Crohn's Disease with Secondary Infliximab Failure
    Sandborn, William
    Vermeire, Severine
    D'Haens, Geert
    Colombel, Jean-Frederick
    Fedorak, Richard
    Spehlmann, Martina
    Wolf, Douglas
    Mitchev, Krassimir
    Jamoul, Corinne
    Abreu, Maria
    Rutgeerts, Paul
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2009, 104 : S452 - S452
  • [9] Certolizumab Pegol Effectiveness in Crohn's Disease Patients with Secondary Failure to Infliximab Is Independent of Infliximab Dosing: Results from the WELCOME Study
    Abreu, Maria T.
    Vermeire, Severine
    Rutgeerts, Paul J.
    Ullman, Thomas A.
    Wolf, Douglas C.
    Sandborn, William J.
    GASTROENTEROLOGY, 2009, 136 (05) : A181 - A181
  • [10] Efficacy of certolizumab pegol is not affected by baseline anti-infliximab antibody status in patients with Crohn's disease with secondary infliximab failure
    Sandborn, W.
    Vermeire, S.
    D'Haens, G.
    Colombel, J.
    Fedorak, R.
    Spehlmann, M.
    Wolf, D.
    Mitchev, K.
    Jamoul, C.
    Abreu, M.
    Rutgeerts, P.
    INFLAMMATORY BOWEL DISEASES, 2009, 15 (12) : S13 - S14
12345